Datopotamab deruxtecan did not reach statistical significance for OS in metastatic or advanced nonsquamous NSCLC in phase III trial

Wildfire pollution may lower survival of lung cancer patients

Breathing in wildfire pollution may make it harder for people with lung cancer to survive, according to a new study from UC Davis Comprehensive Cancer Center researchers.

May 30, 2025

Vol.51 No.21

Clinical Roundup

New biomarker may guide best use of KRAS inhibitors in lung cancer

Researchers from the University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer, following treatment with the KRAS targeted therapy, sotorasib.

May 30, 2025

Vol.51 No.21

Drugs & Targets

FDA grants priority review for sevabertinib in HER2-mutant NSCLC

FDA accepted a new drug application and granted priority review designation for the investigational compound sevabertinib (BAY 2927088), an oral, small molecule, tyrosine kinase inhibitor, for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have activating human epidermal growth factor receptors 2 (HER2) (ERBB2) mutations and who have received a prior systemic therapy.

May 30, 2025

Vol.51 No.21

Drugs & Targets

Cardiac CT scanner receives FDA clearance

Arineta, a provider of cardiovascular imaging solutions, announced that its SpotLight Duo cardiac CT scanner has received 510(k) clearance from FDA for low-dose lung cancer screening. This clearance allows providers to use a single ultra-fast CT platform for both cardiac and lung imaging and diagnostics, delivering more complete care to high-risk patients.

May 23, 2025

Vol.51 No.20

In Brief

NRG Oncology adds new committee leaders in lung cancer and imaging

Kristin HigginsKarthik SundaramKristin Higgins and Karthik Sundaram were named chairs of NRG Oncology’s Lung Cancer Committee and Imaging Committee.

May 09, 2025

Vol.51 No.18

Clinical Roundup

UC Lung Cancer Consortium and AstraZeneca partner to improve early lung cancer detection

The University of California Lung Cancer Consortium and AstraZeneca announced a five-year partnership to expand the Healthy Lungs California initiative, which is aimed at increasing early lung cancer detection and reducing deaths from the disease.

May 02, 2025

Vol.51 No.17

Datopotamab deruxtecan did not reach statistical significance for OS in metastatic or advanced nonsquamous NSCLC in phase III trial

YOU MAY BE INTERESTED IN

Wildfire pollution may lower survival of lung cancer patients

New biomarker may guide best use of KRAS inhibitors in lung cancer

FDA grants priority review for sevabertinib in HER2-mutant NSCLC

Cardiac CT scanner receives FDA clearance

NRG Oncology adds new committee leaders in lung cancer and imaging

UC Lung Cancer Consortium and AstraZeneca partner to improve early lung cancer detection

Renew today!

Subscriber content

Never miss an issue!

Login